Physician

Anan Jawad Haija, M.D.

According to 2025 Medicare claims, Anan Haija, M.D. (NPI: 1487869152) practices rheumatology in the Atlantic City-Hammonton, NJ market, with the plurality of this provider's patient population coming from Atlantic, NJ. This provider's primary affiliated billing organization is VIP RHEUMATOLOGY (NPI: 1457112484; TIN: 934106917) and primary practice location at 08054-1150. Haija is affiliated with the AtlantiCare Health Solutions, Inc. (ACO ID: A4516), participating under the MSSP model.

Haija's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 161 traditional Medicare patients, billed 74,686 HCPCS/CPT codes, and received $654,354 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 669 prescription claims across 199 beneficiaries totaling $763,946 in drug costs, led by Cimzia (2 Pack) (Certolizumab Pegol). Open Payments data shows 141 records totaling $21,288. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $74,053 to $654,354. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	349	879	$74,053
2016	437	1,164	$88,969
2017	488	1,311	$83,840
2018	434	1,048	$70,257
2019	386	901	$69,216
2020	386	1,014	$77,072
2021	379	46,057	$486,781
2022	354	154,535	$1,333,494
2023	378	174,128	$1,578,936
2024	161	74,686	$654,354

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	203	1,086	$736,589
2016	259	1,326	$1,444,271
2017	306	1,562	$1,920,902
2018	297	1,482	$2,291,940
2019	283	1,496	$2,379,693
2020	306	1,738	$2,654,210
2021	316	1,615	$2,108,441
2022	291	1,752	$2,284,054
2023	309	1,652	$2,537,134
2024	199	669	$763,946

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	85	86	$136
96413	Administration of chemotherapy into vein, 1 hour or less	28	96	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	144	407	$105
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	47	333	$62
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	29	48	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Cimzia (2 Pack)	Certolizumab Pegol	35	1,120	$250,808
Simponi Aria	Golimumab	15	576	$107,856
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	63	5,670	$4,487
Cevimeline Hcl	Cevimeline Hcl	19	1,140	$2,970
Methotrexate	Methotrexate Sodium	79	6,327	$2,846

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	141	$21,288	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anan Jawad Haija, M.D.?

Tedicare shows public-source Medicare data for Anan Jawad Haija, M.D. (NPI 1487869152), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anan Jawad Haija, M.D. have ACO affiliation data?

Anan Jawad Haija, M.D. is shown with ACO affiliation data for AtlantiCare Health Solutions, Inc. (MSSP, ACO ID A4516).

What billing organization is linked to Anan Jawad Haija, M.D.?

Anan Jawad Haija, M.D. is linked to VIP RHEUMATOLOGY (billing NPI 1457112484) in the available physician profile data.

Does Anan Jawad Haija, M.D. have Open Payments data?

Anan Jawad Haija, M.D. has 141 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.